Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Phase 3

Completed

Conditions: Leukemia

Interventions: Biological: sargramostim
Drug: cyclophosphamide
Drug: asparaginase
Drug: cytarabine
Drug: dexamethasone
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: imatinib mesylate
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 1929

Registration Number: NCT00002514

Locations: 🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸
MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸
Swedish Medical Center, Englewood, Colorado, United States

and more 91 locations

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Phase 2

Completed

Conditions: Multiple Myeloma and Malignant Plasma Cell Neoplasms
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes

Interventions: Drug: busulfan
Drug: VP-16
Radiation: Fractionated Total Body Irradiation (FTBI)
Drug: Cyclophosphamide

First Posted Date: 2003-01-27

Last Posted Date: 2020-12-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 125

Registration Number: NCT00005797

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: herceptin
Drug: adriamycin
Drug: cyclophosphamide
Drug: taxol

First Posted Date: 2003-01-27

Last Posted Date: 2021-04-29

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 2130

Registration Number: NCT00004067

Locations: 🇺🇸
Cancer Care Center at Northside Medical Center, Youngstown, Ohio, United States
🇺🇸
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 146 locations

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2016-02-03

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 19

Registration Number: NCT00041327

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic/Myeloproliferative Neoplasms
Lymphoma
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: thiotepa
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT00028730

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Drug: mesna
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-08-01

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 69

Registration Number: NCT00002941

Locations: 🇺🇸
All Children's Hospital, St. Petersburg, Florida, United States
🇺🇸
Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸
Children's Hospital Central California, Madera, California, United States

and more 231 locations

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
T-Cell Chronic Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Recurrent Childhood Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Autologous Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 76

Registration Number: NCT00005803

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 2 locations

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Infection

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00046852

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

Phase 2

Completed

Conditions: Lymphoma
Head and Neck Cancer
Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-04

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00007982

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Drug: Allopurinol

First Posted Date: 2003-01-27

Last Posted Date: 2023-08-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 105

Registration Number: NCT00039130

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 28 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy